Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Long-Term Debt Repayments (2019)

Ptc Therapeutics has reported Long-Term Debt Repayments over the past 4 years, most recently at $5.0 million for Q3 2019.

  • Quarterly results put Long-Term Debt Repayments at $5.0 million for Q3 2019, changed N/A from a year ago — trailing twelve months through Dec 2022 was $5.0 million (changed N/A YoY), and the annual figure for FY2022 was $150.0 million, changed.
  • Long-Term Debt Repayments for Q3 2019 was $5.0 million at Ptc Therapeutics, up from $12000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for PTCT hit a ceiling of $5.0 million in Q3 2019 and a floor of $5.0 million in Q3 2019.